Co-Authors
This is a "connection" page, showing publications co-authored by DAVID TWEARDY and MOSES MAKOKHA KASEMBELI.
Connection Strength
5.710
-
Aberrant function of pathogenic STAT3 mutant proteins is linked to altered stability of monomers and homodimers. Blood. 2023 03 23; 141(12):1411-1424.
Score: 0.886
-
Corrigendum to "TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain" [Biochem. Pharmacol. 192 (2021) 114688]. Biochem Pharmacol. 2022 Jan; 195:114860.
Score: 0.809
-
TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain. Biochem Pharmacol. 2021 10; 192:114688.
Score: 0.788
-
Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment. Int J Mol Sci. 2018 Aug 05; 19(8).
Score: 0.643
-
Modulation of STAT3 folding and function by TRiC/CCT chaperonin. PLoS Biol. 2014 Apr; 12(4):e1001844.
Score: 0.477
-
SH2 domain binding to phosphopeptide ligands: potential for drug targeting. Front Biosci (Landmark Ed). 2009 01 01; 14(3):1010-22.
Score: 0.331
-
Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility. Pharmacol Res. 2021 07; 169:105637.
Score: 0.194
-
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Pharmacol Rev. 2020 04; 72(2):486-526.
Score: 0.180
-
Correction: Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2019 02 22; 10(16):1603.
Score: 0.167
-
Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome. Blood. 2016 12 29; 128(26):3061-3072.
Score: 0.142
-
Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016 May 03; 7(18):26307-30.
Score: 0.137
-
Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance. Biomed Res Int. 2016; 2016:1959270.
Score: 0.135
-
Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis. Int J Mol Sci. 2015 Nov 06; 16(11):26706-20.
Score: 0.133
-
Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lung Cancer. 2015 Nov; 90(2):182-90.
Score: 0.131
-
Contribution of chaperones to STAT pathway signaling. JAKSTAT. 2014; 3(3):e970459.
Score: 0.124
-
Monoclonal Antibodies Specific for STAT3? Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer. Cancers (Basel). 2014 Sep 29; 6(4):2012-34.
Score: 0.123
-
Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One. 2009; 4(3):e4783.
Score: 0.084
-
Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease. Am J Physiol Renal Physiol. 2020 07 01; 319(1):F84-F92.
Score: 0.046
-
Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors. Org Biomol Chem. 2020 05 06; 18(17):3288-3296.
Score: 0.045
-
Chaperonin TRiC/CCT Recognizes Fusion Oncoprotein AML1-ETO through Subunit-Specific Interactions. Biophys J. 2016 06 07; 110(11):2377-2385.
Score: 0.035
-
PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Rep. 2016 Apr 26; 15(4):843-856.
Score: 0.034
-
Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO. J Biol Chem. 2016 Feb 26; 291(9):4732-41.
Score: 0.034
-
Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity. Angew Chem Int Ed Engl. 2015 Oct 26; 54(44):13085-9.
Score: 0.033